A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Inclusion Criteria:

• Aged ≥18 years with a diagnosis of adenocarcinoma of the prostate (Gleason graded, allstages) where endocrine treatment is indicated.

• Caucasian origin.

• Able to provide written Informed Consent and willing and able to comply with trialprocedures.

• Body mass index (BMI) between 18.5-30 kg/m2.

• Has a life expectancy of at least one year.

Exclusion Criteria:

• Current hormonal management of prostate cancer.

• Previous endocrine therapy for prostate cancer within 3 months prior to the screeningvisit.

• Any medical injection therapy that might interfere with degarelix injections.

• Patients with advanced muscle atrophy or cachexia which in the Investigator's opinionwould preclude or pose risks of complications following ventrogluteal i.m. injectionof degarelix.

• Any medical condition that could be aggravated or may cause extreme discomfort duringthe trial period or could cause a moderate risk to a patient (significant heart, renalor liver disease).

• Chronic pain syndrome or any continuous pain reported by the patient that, accordingto the judgement of the Investigator, could limit the evaluation of injection relatedpain.